AI-powered drug discovery for aging
Insilico Medicine combines artificial intelligence with biology to discover novel treatments for aging and age-related diseases. Their Pharma.AI platform has identified drug candidates in a fraction of the time and cost of traditional drug discovery.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| INS018_055 | Idiopathic Pulmonary Fibrosis | Phase 2 | AI-discovered |
| ISM3091 | Inflammatory Bowel Disease | Phase 1 | AI-discovered |
Three companies, three different gene editing technologies, three different investment theses. Here's how Intellia (CRISPR), Beam (base editing), and Prime Medicine (prime editing) compare as investments in 2026.
How artificial intelligence is transforming gene editing, from designing better guide RNAs to predicting protein structures and engineering novel gene editors.
Editas Medicine was the first CRISPR company, co-founded by Feng Zhang with Broad Institute patents. But while competitors won FDA approvals, Editas struggled. Here's what happened.